QUÉBEC CITY, June 13, 2023 /PRNewswire/ - Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.
Read MoreOne of Aplantex’ technical partners, the Centre d’études des procédés chimiques du Québec (CEPROCQ) represented by Yacine Boumghar, Ph.D, has received a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support the continued development of Aplantex’ innovative process to produce valuable molecules commonly used by the pharmaceutical, cosmetics, and agrifood industries.
Read MoreBOSTON — The Manitoba government’s visionary new Life Sciences Strategy will power innovation and boost the province’s reputation as an internationally renowned hub for biosciences, Economic Development, Investment and Trade Minister Jeff Wharton announced today at the BIO International Convention in Boston.
Read MoreMONTRÉAL, June 7, 2023 – Developing new generations of immunotherapies to treat currently incurable pediatric leukemia is the mission of Neomabs Biotechnologies, a new Montreal-based biotechnology company specializing in the discovery and development of innovative oncology therapies.
Read MoreBOSTON, June 6, 2023 /PRNewswire/ - Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform technology to engineer and develop novel protein subunit vaccines, today announced a clinical supply agreement with Biodextris Inc.
Read MoreBoston, Massachusetts – June 5, 2023 – CQDM is delighted, at BIO2023, in the presence of Minister Fitzgibbon, Quebec’s Minister of the Economy, Innovation and Energy (MEIE) to announce that Merck Canada, has renewed its commitment to CQDM with $3.0M in funding to support the development of innovative technologies in biopharmaceutical research.
Read MoreMONTREAL and BOSTON, June 5, 2023 /CNW/ - Oncopole, Fonds de recherche du Québec - Santé (FRQS) cancer division, is proud to announce major investments that bolster its unique public-private partnership model dedicated to the fight against cancer. Building on its dynamism and ability to mobilize stakeholders in the life sciences community, Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada.
Read MoreMontreal, Toronto, Vancouver (June 6, 2023) – adMare BioInnovations, a leader in the Canadian life sciences sector, is pleased to announce the launch of the adMare Institute, a new voice aimed at advancing the life sciences and related public policy in Canada. The announcement was made today at the prestigious BIO International Conference in Boston.
Read MoreMONTREAL, June 5, 2023 /PRNewswire/ - Paraza Pharma is pleased to announce the appointment of Edward W. (Ted) Marple, A.B. (Harvard), MBA (Virginia) as Executive Vice-President, Development.
Read MoreGrant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent.
MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.
Read Morecreation and exchange of innovative ideas.
Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal. Located in the iconic Place Gare Viger, the office has been designed to provide a modern workplace that meets the needs of Novartis' associates and facilitates closer collaboration with key stakeholders.
Read MorePfizer Canada ULC announces the launch of its Healthcare Hub, an initiative with Canadian tech and innovation startups to scale up health solutions, with the goal of enhancing outcomes and the patient experience in important areas of need in Canadian healthcare.
Read MoreenGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq.
Read MoreThe Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph through a partnership with OmniaBio Inc., CCRM and the university. The training program, to begin in summer 2023, will cater to recent post-secondary graduates, industry professionals and companies growing their roster of clean room manufacturing staff. The fast growth of cell and gene therapies (CGTs) has made it a challenge for the global industry to keep up with talent requirements. This new CGT technical training site will begin to address the industry's critical training needs and represents the first stage of a larger, multi-site training strategy for CATTI.
Read MoreBIOQuébec: a powerful facilitator for your organization
When Anie Perrault, then executive director, met Frédéric Leduc for the first time in 2014, she convinced him to become a member by highlighting the benefits of a strong, extensive network and the possibility of makinghis voice heard via BIOQuébec. Frédéric immediately seized this unique opportunity to meet potential clients and collaborators for the young biotech he had co-founded.
Read MoreAs a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”. The $165M investment, bolstered by another $185M+ commitment from academic and industrial partners will go towards supporting fundamental RNA research, including drug discovery efforts, which aligns perfectly with our company's mission and values.
Read MoreBausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray).
RYALTRIS has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Read MoreAs part of the Effervescence conference, the Centre Québécois d'Innovation en Biotechnologie (CQIB) announced a contribution of $420,000 to seven startups for the clinical data validation of new medical technologies.
Read MoreMcGill is the recipient of a landmark $165 million CFREF grant to launch DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R), a first-of-its-kind global research effort specializing in the development and delivery of more inclusive genomic-based RNA therapeutics. D2R will receive significant support from more than 50 partners, including many from academia and industry, who have all pledged to invest in the research, which brings the total amount invested in D2R to $353 million.
Read MorePharma in silica inc. announces today the closing of a $ 2,000,000 funding to continue the development of OpPacli™, an original nanomedicine developed to provide patients suffering from certain solid cancers with a well-tolerated and more efficient chemotherapy.
Read More